Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SK Plasma Co. Ltd. is building a new blood product plant with an investment of KRW300 billion or about $250 million. The facility is set to be constructed in Indonesia.
Once in full operation, the new plant is expected to have the capacity to produce one million liters of blood products per year. SK Plasma will break ground some time this year, and the plant will be completed in two years.
Business insiders revealed earlier this week that the South Korean firm that produces albumin, immunoglobulin, coagulation factors, and antithrombin received the final approval for the construction of its plant from the Ministry of Health and Welfare of Indonesia not long ago. The facility will process the collected blood plasma and turn them into therapeutic agents.
Business Korea reported that for this project, SK Plasma would partner with Infion through a joint venture (JV) agreement. It is an Indonesian pharmaceutical company that will SK Plasma with its business operation in the country.
The size of the company’s upcoming plant in Indonesia is said to have a bigger production capacity than its facility in Andong, South Korea. It will offer 1.6 times more than the 600,000-liter capacity of its Korean plant.
In any case, the new factory will produce six types of blood products like Liv Gamma and albumin. The Korea Herald reported that albumin and immune globulin, which will be produced at the SK Plasma Indonesian facility, are typically used for patients with hemophilia and immunodeficiency diseases. These are made through strict and rigorous processes, including the centrifugation of blood collected from blood donation drives.
The blood products will ensure a stable supply in Indonesia, where the population is already close to 300 million. It was said that 100% of the citizens are currently dependent on imports of blood products.
“By transferring technologies relating to blood products and installing a manufacturing facility in a country that has no related infrastructure, SK Plasma seeks to create new business opportunities and reach the company’s ESG goals,” Kim Seung Joo, SK Plasma’s chief executive officer, said in a statement.
